IO Biotech, Inc. (IOBT)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Qasim Iftikhar Ahmad M.D. | Chief Medical Officer | 503.28k | -- | 1971 |
| Prof. Inge Marie Svane M.D., Ph.D. | Founder & Clinical Advisor | -- | -- | -- |
| Prof. Mads Hald Andersen M.D., Ph.D. | Co-Founder & Scientific Advisor | -- | -- | -- |
| Anders Ljungqvist | Founder | -- | -- | -- |
| Prof. Per Thor Straten | Founder | -- | -- | -- |
| Ms. Amy B. Sullivan M.B.A. | Chief Financial Officer | 391.24k | -- | 1971 |
| Mr. Eric Faulkner M.B.A. | Chief Technical Officer | -- | -- | -- |
| Mr. Daniel G. Mannix Ph.D. | Senior Vice President of Regulatory Affairs | -- | -- | -- |
| Dr. Faical Miyara Ph.D. | Chief Business Officer | -- | -- | -- |
| Dr. Marjan Shamsaei Pharm.D. | Senior VP of Commercial Development & Portfolio Lead | -- | -- | -- |
IO Biotech, Inc.
- Sector:?
- Healthcare
- Industry:? Biotechnology
- Full Time Employees:?
- 74
Description
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.
Corporate Governance
Upcoming Events
Upcoming Events Information Not Available
Recent Events
August 9, 2024 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission